Searchable abstracts of presentations at key conferences in endocrinology

ea0090d1.2 | Should diabetes insipidus be re-named? | ECE2023

Con: Should diabetes insipidus be re-named?

Tsagarakis Stylianos

Recently, a position statement of a working group for renaming diabetes insipidus (DI) appeared in several renowned endocrine journals aiming to promote a change in the established name of DI. According to this position statement, the major arguments for renaming DI are: (a) it does not optimally reflect the underlying pathophysiology (b) it is often confused with diabetes mellitus (DM) leading to treatment errors and consequent adverse outcomes for patients. Although the abov...

ea0049d1.2 | Is there a role for medical therapy for non-functioning pituitary adenomas? | ECE2017

Is there a role for medical therapy for non- functioning pituitary adenomas? - AGAINST

Tsagarakis Stylianos

Non-functioning pituitary adenomas (NFPA) are the second most common variant of pituitary tumors. They are presented by compression symptoms, hypopituitarism and in rec as incidental findings during brain imaging. When symptomatic, primary therapy for NFPAs is surgery most commonly by the trans-sphenoidal (TSS) approach. Medical therapy is not generally recommended in this setting, particularly when immediate decompression of the optic chiasm is needed. Despite the debulking e...

ea0022s20.3 | The endocrine incidentaloma | ECE2010

Adrenal incidentalomas

Tsagarakis Stylianos

Incidentally detected adrenal masses are increasingly encountered in clinical practice due to better availability and accessibility of imaging procedures and are considered to be amongst the most common tumors in humans, with an estimated prevalence ranging from 0.4 to 4.4%. Malignancy is rare amongst patients with adrenal incidentalomas presenting in an endocrine clinic. The imaging phenotype is very helpful in distinguishing benign adenomas from malignant lesions. From the e...

ea0014s1.3 | Hypopituitarism | ECE2007


Tsagarakis Stylianos

Hypocorticotropism refers to ACTH insufficiency, which may be partial or complete, isolated or combined, genetic or acquired, pituitary or hypothalamic in origin. As a result it leads to secondary adrenal failure. Adrenal secretion of cortisol and of adrenal androgens is mainly affected; aldosterone secretion is normal. Symptoms of hypocorticotropism include progressive malaise and weight loss. Because aldosterone secretion is intact salt wasting, volume contraction and hypoka...

ea0090p556 | Adrenal and Cardiovascular Endocrinology | ECE2023

Cardiometabolic and bone health in postmenopausal women with glucocorticoid replacement therapy due to adrenal insufficiency; where do we stand

Kardalas Efstratios , Angelousi Anna , Argyro Vassiliadi Dimitra , Tsagarakis Stylianos

Background: Individuals with adrenal insufficiency (AI) receive life-long glucocorticoid (GC) replacement therapy (CGRT), which often exceeds normal daily physiological GC production, leading to detrimental effects on cardiometabolic parameters and bone health.Objective: Assessment of glucose, lipid and bone metabolism in AI postmenopausal patients in relation to the cause of AI and the CGRT dose.Methods: 114 AI postmenopausal wome...

ea0090p535 | Late-Breaking | ECE2023

Occurrence of thyroid autoimmunity, metabolic disorders and malignancy in patients with primary, non-syndromic hyperparathyroidism

Kardalas Efstratios , Ntali Georgia , Argyro Vassiliadi Dimitra , Tsagarakis Stylianos

Background/aim: Primary hyperparathyroidism (pHPT) is a relatively common endocrine disorder, which is often asymptomatic and thus diagnosed during routine biochemical testing. Emerging scientific data supports the theory that non-syndromic pHPT patients may be at increased risk for thyroid autoimmunity, metabolic disorders and malignancy.Materials and methods: A cohort of 227 pHPT (61 male and 166 female) and 244 non-pHPT (75 male and 169 female) patien...

ea0090p538 | Late-Breaking | ECE2023

How did COVID-19 pandemic affect the glycemic regulation of patients with type 1 diabetes mellitus and continuous insulin infusion systems? Experience of a single diabetes center

Kardalas Efstratios , Katechakis Nikolaos , Argyro Vassiliadi Dimitra , Tsagarakis Stylianos

Background and Aims: The COVID-19 pandemic severely affected the glycemic regulation of adult patients with type 1 diabetes (T1D). The aim of this study was to evaluate the impact of this pandemic on glycemic control in T1D patients with continuous subcutaneous insulin infusion (CSII) systems.Methods: A cohort of adult T1D patients with CSII was retrospectively evaluated. Data regarding number visits to our diabetes clinics, total daily insulin dose (TDI...

ea0022p45 | Adrenal | ECE2010

High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: implications to management

Vassiliadi Dimitra , Ntali Georgia , Vicha Eirini , Tsagarakis Stylianos

Although the prevalence of subclinical hypercortisolism (SH) in unilateral incidentalomas (UI) has been extensively reported, patients with bilateral incidentalomas (BI) have not been thoroughly investigated. Moreover, the management of BI poses great dilemmas if surgery is considered, since bilateral adrenalectomy leads to life-long replacement. In the present study, we aimed to describe the characteristics of patients with BI in comparison to their unilateral counterparts. W...

ea0081yi1 | Young Investigator Awards | ECE2022

Excessive bilateral adrenal hyperplasia associated with aldosterone synthase (CYP11B2) deficiency

Diamantopoulos Aristidis , Mourelatos Panagiotis , Sertedaki Amalia , Botoula Efthimia , Vassiliadi Dimitra , Tsagarakis Stylianos

Introduction: Congenital adrenal hyperplasia (CAH) encompasses a group of enzymatic defects in cortisol biosynthesis resulting in adrenal hyperplasia through chronic compensatory ACTH stimulation. Aldosterone synthase deficiency, however, is associated with normal cortisol secretion and there are no reports on whether it may be associated with adrenocortical hyperplasia.Case Presentation: A 37-year-old, Greek female was referred for further investigation...

ea0086p178 | Bone and Calcium | SFEBES2022

Bone metabolism and bone mass density following successful treatment of catecholamine secreting tumors

Kardalas Efstratios , Ntali Georgia , Mouchtouris Panagiotis , Papachristou Aglaia , Lavrentaki Aikaterini , Tsagarakis Stylianos

Introduction: Pheochromocytomas and paragangliomas(PPGLs) are catecholamine-secreting tumors. Catecholamine excess contributes to bone resorption and secondary osteoporosis. PPGLs are treated surgically but limited data exists on the subsequent effect on bone status.Aim: To evaluate bone metabolism(BM) and bone mass density(BMD) before and after successful surgery of PPGLs.Methods: A retrospective study on (BM) of (PPGLs) patients ...